Celltrion Pushes ‘Biobetters’ Concept With Remsima SC
Subcutaneous Biosimilar Infliximab Delivers On The Promise Of Biobetters
• By David Wallace
Celltrion says its subcutaneous formulation of infliximab makes the biosimilar better than the Remicade original • Source: Shutterstock 
